Study of Tofacitinib in Refractory Dermatomyositis: An Open-Label Pilot Study of Ten Patients.
Julie J PaikLivia A Casciola-RosenJoseph Yusup ShinJemima AlbaydaEleni TiniakouDoris G LeungLaura Gutierrez-AlamilloJamie PerinLiliana FloreaCorina AntonescuSherry G LeungGrazyna PurwinAndrew KoenigLisa Christopher-StinePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
This is the first prospective, open-label clinical trial of tofacitinib in DM that demonstrates strong clinical efficacy of a pan-JAK inhibitor, as measured by validated myositis response criteria. Future randomized controlled trials using JAK inhibitors should be considered for treating DM.
Keyphrases
- locally advanced
- clinical trial
- open label
- rheumatoid arthritis
- end stage renal disease
- interstitial lung disease
- randomized controlled trial
- newly diagnosed
- phase ii
- chronic kidney disease
- study protocol
- peritoneal dialysis
- prognostic factors
- type diabetes
- disease activity
- systemic sclerosis
- adipose tissue
- current status
- glycemic control
- systematic review
- patient reported outcomes
- idiopathic pulmonary fibrosis
- double blind